Solara Active Pharma Sciences Ltd, headquartered in India, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. Founded in 2017, the company has quickly established itself as a key provider of high-quality products, catering to both domestic and international markets. With a focus on innovation and sustainability, Solara offers a diverse range of APIs, particularly in the therapeutic areas of anti-infectives, cardiovascular, and central nervous system medications. The company’s commitment to quality and regulatory compliance has earned it a strong market position, with notable achievements in securing approvals from major global regulatory bodies. Solara's strategic operational regions extend across Asia, Europe, and the Americas, reinforcing its status as a trusted partner in the pharmaceutical supply chain.
How does Solara Active Pharma Sciences Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Solara Active Pharma Sciences Ltd's score of 18 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Solara Active Pharma Sciences Ltd reported total carbon emissions of approximately 54,428,000 kg CO2e, comprising 11,168,000 kg CO2e from Scope 1 and 43,425,000 kg CO2e from Scope 2. This data reflects their commitment to transparency in emissions reporting within the pharmaceutical sector. For 2022, the company recorded similar emissions, with 10,169,000 kg CO2e from Scope 1 and 50,693,000 kg CO2e from Scope 2. The consistency in emissions figures indicates a stable operational footprint, although specific reduction targets have not been disclosed for these years. Solara has committed to achieving net-zero emissions, demonstrating a proactive approach to climate action. Their near-term targets are classified as "Committed," signalling their intention to align with industry standards for sustainability. However, no specific timelines or quantitative targets have been provided. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector in India, where it is essential to address climate impacts. As of the latest updates, Solara has not inherited emissions data from any parent or related organizations, ensuring that their reported figures are solely reflective of their own operations.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 10,169,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 50,693,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Solara Active Pharma Sciences Ltd has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Solara Active Pharma Sciences Ltd's sustainability data and climate commitments